1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

First US Home Collection COVID-19 Test Gets Green Light

US regulators have authorized the first COVID-19 test that lets people take a sample of mucus inside their nose at home to check for the novel coronavirus. The maker of the test, LabCorp, says the test will be available in most states within the next few weeks – but health care workers will be given the tests before the general public.

Molecular Bio Lab Lab Corp.
A LabCorp technician running a diagnostics test • Source: Source: LabCorp

The US Food and Drug Administration announced on 21 April that it reissued an emergency use authorization for Laboratory Corporation of America’s (LabCorp) COVID-19 RT-PCR Test that now lets users take a sample of their mucus from the confines of their home. The test is intended to make it easier for people suspected of having the SARS-CoV-2 virus to determine whether they’re positive and to help reduce the risk of spreading the disease.

The FDA issued the EUA for the tests about a month ago but has now updated that authorization to allow...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By Elizabeth Orr

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 
• By Brian Bossetta

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Finland Cracks Down On Software That Needs Regulating As A Medical Devices

 
• By Amanda Maxwell

Finland has initiated a project to improve the effectiveness of the monitoring of software intended for medical use and to ensure that software placed on its market meets the requirements set for it. 

More from Policy & Regulation

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By Elizabeth Orr

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By Jung Won Shin

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.